Therapeutic Antibodies, Services
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
82
NCT05338931
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 15, 2022
Completion: Sep 15, 2030
Loading map...